Quanta Treats First Patients with Advanced Haemodialysis System SC+

ALCESTER, England, October 26, 2015 /PRNewswire/ --

Positive data reported from initial ten treatments 

Over 40 treatments now successfully completed 

Quanta Fluid Solutions Ltd ("Quanta" or the "Company"), a pioneer of advanced haemodialysis solutions, today announces it has successfully treated the first patients with SC+, its portable, cartridge-based haemodialysis system.

The treatments were part of a pilot study designed to demonstrate safety, performance and usability of SC+ in a clinical setting with human dialysis patients. The results showed that all dialysis therapies were successfully and safely completed with no adverse events. Essential performance criteria, including urea clearance and ultrafiltration rate, were assessed and achieved their prescribed targets, clearly meeting the primary endpoints of the study.

Patients and clinicians were also asked to rate SC+ in terms of usability in comparison to standard dialysis systems. Positive feedback was given on the simplicity and compact size of the machine, the unique cartridge concept and on the quietness of SC+ when running.

The first ten treatments were performed with six patients over a two-week period at Nottingham University Hospitals NHS Trust in the United Kingdom. These treatments were provided as in-centre, nurse-led haemodialysis therapy sessions at standard dialysate and blood flow-rates. Participants included male and female patients with chronic end stage renal disease, aged from 40 to 79 years-old and with weights ranging between 79.5kg and 154kg.

Since then, patients have continued to be treated at Nottingham, reaching over 40 successful treatments to date.

John E. Milad, Chief Executive Officer of Quanta, commented: "These first successful treatments represent an important milestone for Quanta, marking our transition into the clinical arena with SC+. All primary endpoints were successfully achieved without any adverse events, and feedback from patients and clinicians continues to be positive. This is a resounding validation of SC+ and its potential to improve the lives of dialysis patients. We look forward to expanding our pilot activities and increasing the availability of SC+."

Dr Charlotte Bebb, Consultant Nephrologist at Nottingham University Hospitals NHS Trust and Principal Investigator, said: "Patients and physicians need flexibility in their treatment and options on where and how they dialyse: in the dialysis unit, self-treatment in the dialysis unit or at home. Quanta's SC+ can do all three and is a significant improvement on current treatment options. Many machines can be used for self-care and at home, however, they are large, unwieldy and complex; SC+, which is a smaller, simplified machine, offers real advantages. We are pleased to be supporting new innovation in dialysis and look forward to the continued patient studies for SC+ in Nottingham."

About SC+ 

SC+ is designed to bring flexibility to dialysis patients and physicians by supporting all treatment regimens, from nurse-assisted care and patient self-care in-centre, to home haemodialysis. SC+ is the only portable, compact haemodialysis system capable of operating at the higher flow rates typically used to treat patients in-centre by traditional machines. The technology behind SC+ is based on an innovative and unique design that incorporates all fluid management activities onto a single-use disposable cartridge.

About Quanta 

Quanta is developing advanced haemodialysis systems for use in the clinic and the home. The Company has obtained CE Mark for its flagship product SC+, which is a portable, compact cartridge-based haemodialysis system. SC+ is designed to offer ease-of-use and flexibility whilst facilitating self-care and supporting dialysis patients across the entire continuum of care.

Quanta is privately owned and based in Alcester, UK. The Company was founded in 2008 as a spin out from the FTSE 250 engineering company IMI plc, which remains an investor, with additional funding provided by a group of leading venture capital investors specialised in healthcare: NBGI Ventures, Wellington Partners, Seroba Kernel, b-to-v Partners, ALIAD, Seventure Partners and Kuwait Life Sciences Company.

Quanta is dedicated to creating a paradigm shift in renal care and to improving the lives of dialysis patients.

For more information please visit: http://www.quantafs.com.

About End Stage Renal Disease and Haemodialysis  

Lifestyle choices, modern diet and increased life expectancy are all negatively impacting renal health across the globe and End Stage Renal Disease affects millions of patients worldwide. Haemodialysis is a life-saving treatment delivered to an estimated 2.4 million people globally, with this figure expected to double in the next decade.

At present, haemodialysis is primarily provided by specialist clinics and centres. However this means that the patient is not in control of when they can dialyse. Clinical evidence suggests that more frequent dialysis improves outcomes and patient's quality of life, and a number of studies have shown that 30-40% of patients would be capable of performing self-dialysis.

Issues of patient benefit, cost and clinic capacity are driving the growth of home and self-care modalities of haemodialysis, but a major factor limiting the growth of self-care and home haemodialysis is the lack of convenient, portable and easy-to-use dialysis systems. SC+ addresses these issues and puts the patient at the centre, allowing them to take greater control of their treatment.

For more information about Quanta, please contact:

Quanta

John E. Milad, Chief Executive Officer
T: +44-(0)1789-400043
E: [email protected]

Consilium Strategic Communications

Amber Fennell / Matthew Neal / Lindsey Neville
T: +44-(0)203-709-5708
E: [email protected]

SOURCE Quanta Fluid Solutions Ltd